The Europe link is real but narrow
Most of this quarter's biotech news comes from US-listed companies. The clearest European data point in our dossier is BioArctic, listed in Stockholm, whose partner Eisai reported Leqembi sales of JPY 29.3 billion for the second quarter of 2026. That produced a royalty to BioArctic of SEK 179 million, about 10 percent higher than the same quarter of 2025.1 Our dossier contains no EU regulatory ruling for this group of companies, so we do not offer one. What it does contain is a picture of how pipeline progress and market mood are linked, and that matters to anyone holding European healthcare shares, directly or through a fund.
Commercial income: the BioArctic example
BioArctic's headline growth of 10 percent understates the underlying trend, according to the company. The second quarter of 2025 included a one-time stockpiling effect in China of around JPY 5.3 billion. Excluding it, BioArctic says royalty revenues in Q2 2026 grew approximately 43 percent year over year.1 BioArctic's own words: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."1 This is a company's statement about its own figures, published through a newswire. Of the 6,752 claims we have checked from this wire service, 54% held up, so the 43 percent figure is worth watching but not worth treating as settled.1
The example matters because a royalty is income that does not depend on a capital raise. A company with royalty income can fund research without selling new shares at a bad moment. Most of the companies below cannot.
The clinical-stage companies: milestones, not income
Scribe Therapeutics, listed on Nasdaq under SCTX, reported third-quarter results on 12 November 2026. It is enrolling a first-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for lowering LDL cholesterol, with initial clinical data expected in the first half of 2027.2 Our narrative record puts its cash at $174.2 million.3 Scribe also expanded its collaboration with Sanofi, which gives Sanofi access to its ELXR silencing technology.2 The company's case rests on a patient problem. It says current LDL-C lowering therapies are limited by poor persistence, with studies showing 50% to 70% of patients discontinue treatment within one year.2 It also says people with naturally occurring PCSK9 loss-of-function variants have been reported to have 28% lower mean LDL-C and up to 88% lower coronary heart disease risk, and that STX-1150 aims to mimic that protection.2 These are Scribe's claims, not trial results. The first human data are still months away.
Vor Bio reported final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, a kidney disease. The annualized eGFR slope (a measure of kidney filtering decline) was -0.6 versus -5.7 mL/min/1.73 m² per year for placebo, a 5.1 difference with p<0.001. The company also reported 89% and 81% reductions in the risk of confirmed 30% and 40% eGFR declines, with a favorable safety profile.4 This is the strongest clinical result in our dossier, though it comes from the company's own release.
Akari Therapeutics, with offices in Tampa and London, is developing antibody drug conjugates (ADCs, cancer drugs that deliver a toxin to a tumour). Its CEO describes planned Phase 1 development of AKTX-101 in mid-2027.5 The company says ADC-refractory patients are a significant, growing unmet need and an exclusive opportunity for its novel payload, which current and most future ADCs will not be able to access.5 That is a sales pitch for a drug years from approval. Our narrative record also notes Incyte presented pancreatic cancer combinations at ESMO.3
What a large cash balance looks like: Incyte
Incyte is the one company where SEC-filed numbers let us measure the cushion. Its cash stood at $3,097,817,000 at the end of fiscal 2025, $3,461,114,000 in the first quarter of 2026, $3,982,375,000 in the second quarter and $3,275,881,000 in the third.6 That is roughly three and a quarter billion dollars, against fiscal 2025 capital spending of $48.7 million.7 Fiscal 2024 capital spending is recorded at exactly the same $48.7 million, which is unusual enough that we flag it for checking rather than treat as a trend.7
The history shows how much a balance can move. Incyte's cash was $1,687,829,000 at the end of fiscal 2024, and $987,293,000 in the second quarter of 2024.6 A company that can swing that much in a year is one whose runway depends on how it funds itself, not on a fixed number.
The market mood: Via News's analysis
Via News's analysis of the data suggests biotech funding is tied to the mood in AI and technology shares.3 The events behind that view are dated. On 30 October 2026 a $1 trillion tech selloff deepened fears of an AI bubble, and the Nasdaq 100 had its worst day since June.8 The next day OpenAI cut its funding target by $10 billion.9 On 1 November, Binance users withdrew $3.6 billion when the exchange reopened after a hack.10 For scale, a trillion dollars is a thousand billions. Many readers will hold some of that value through a global index fund, though our dossier does not give the weightings and we do not guess them.
The link to biotech is that AI is being built into drug discovery. Radical Numerics says AI-designed viruses have treated its first patient, in an experimental treatment for drug-resistant E. coli.11 If investors tire of AI stories, firms that sell an AI angle may find it harder to raise money. That is our reading, not a measured result, and the dossier contains no financing data to test it.
Where the evidence is weak
The dossier also includes a claim from Generation Lab that its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."12 That is the company's description. MIT Technology Review, which reported it, has a measured reliability in our system of only 6% of 16 checked claims holding up, so we treat it as an unverified marketing statement.12 Similarly, an AbbVie versus Eli Lilly comparison from the Motley Fool, which supports the Lilly demand point in our narrative, comes from a source where 31% of 58 checked claims held up.3
One more European data point is a hire, not a result. Idorsia appointed Begoña Carreño-Gómez as Chief Business Development Officer, effective 1 November 2026.13 Business development heads do the deal-making that cash-limited companies rely on. The dossier says nothing further about Idorsia's plans.
What to watch
The first human data for STX-1150 are due in the first half of 2027.2 Akari's AKTX-101 is planned to enter Phase 1 in mid-2027.5 BioArctic's next Leqembi royalty will show whether the 43 percent underlying growth holds.1 Incyte's next quarterly cash figure will show whether its balance keeps falling from the second-quarter peak.6 And the funding mood: if the tech selloff of 30 October is followed by further falls, expect smaller raises from companies without royalty income.

